February 25, 2008

IRI to concentrate on operation of antibodies extraction

Biotech company IRI Separation Technologies (IRI) has signed a distribution agreement with Vanderpol's Eggs Ltd (VEL) in which VEL will take over distribution of sales of egg products so that IRI would be able to concentrate on the extraction of antibodies from eggs.

IRI runs two major operations - an egg-breaking facility and a separation facility where antibodies are extracted from egg yolks - and the agreement has now allowed VEL to take over the distribution and sales operations of the egg-breaking facility to facilitate IRI's focus on antibodies extraction.

IRI specialises in the extraction of polyclonal immunoglobulin antibodies, and the company will continue to use egg yolks from its egg-breaking facility, which will be transferred to the company's separation facility.

The company intends to market the antibodies for use in foods, with plans to elevate it to a health product.